RxDoctor Payments Data

Derek Towery, MD

Dermatology · Joplin, MONPI 1346237351

Payments from drug & device makers

$8,234in general payments, 2019–2025

Across 466 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Novartis$731
  • Lilly USA, LLC$543
  • Sanofi$509
  • E.r. Squibb & Sons, L.L.C.$332
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,91996%
  • Education$3164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,234 in reported general payments places this provider in the 70th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$527,426
Medicare patients
2,037
Services billed
11,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab65$277,303
OtezlaApremilast19$120,514
Cosentyx Unoready PenSecukinumab11$118,300
Fluorouracil134$10,373
Clobetasol Propionate125$5,821
Triamcinolone Acetonide223$2,470
Doxycycline Hyclate133$1,773
Colchicine13$1,445
Metronidazole22$1,237
MethotrexateMethotrexate Sodium80$1,230
Imiquimod31$889
Hydroxyzine Hcl45$578
CiclopiroxCiclopirox Olamine28$518
Clindamycin Phosphate19$444
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc41$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$299$120,51419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 263 dermatology providers in Missouri.

Other dermatology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →